ibiojohn.wordpress.com
Akorn divests ECR Pharma shortly after acquisition
Akorn, Inc. announced that it has sold its subsidiary, ECR Pharmaceuticals (ECR), to Valeant Pharmaceuticals (NYSE/TSX: VRX) for $41 million in cash and assumption of certain liabilities.